Navigation Links
Outreach Program to Increase Awareness of New Advances in Biomedical Research to Treat Down Syndrome Cognitive Impairment
Date:3/8/2010

CHICAGO, March 8 /PRNewswire-USNewswire/ -- Research Down Syndrome (RDS) has launched an international outreach program to focus awareness and support for the rapidly advancing area of biomedical research leading to safe and effective approved medical therapies to treat cognitive impairment in individuals of all ages with Down syndrome -- improving memory, learning and communication.

Until the past decade, research to understand and treat the cognitive impairments associated with Down syndrome had been largely unexplored, according to Robert C. Schoen, Ph.D., President of RDS.  "In 2000, researchers working on the Human Genome Project fully sequenced human chromosome 21, spurring a renewed interest in exploring the causes of the intellectual impairments of Down syndrome.  In the last five years, applying modern scientific tools and techniques, researchers have made significant progress toward understanding and treating the cognitive issues associated with Down syndrome, successfully correlating cognitive impairment with specific genes, in specific cells, during specific stages of development," said Schoen.  These studies now provide the promise of biomedical therapies for improving memory and learning in individuals with Down syndrome.

This research also offers hope for an increased understanding of the neurobiological basis of Alzheimer's disease. All persons with Down syndrome exhibit cognitive impairment, usually in the mild to moderate range, and, by age 40, virtually all exhibit the brain pathology of Alzheimer's, with at least half eventually developing Alzheimer's disease, according to Schoen. "Scientists continue to find associations between Down syndrome and Alzheimer's disease which opens promising new paths of investigation".    

A leading researcher in the genetics and neurobiology of cognitive dysfunction in Down syndrome, Roger Reeves Ph.D., from Johns Hopkins University, notes that plateaus in medical research can, at some point, give way to rapid advances. He further explains that "Down syndrome cognitive research is at this stage now, and I am extremely encouraged by the ongoing advances on several fronts in research institutions across the world."

In recent decades, improved health care, expanded education and community opportunities, and the support of families and advocacy groups have improved the quality of life for individuals with Down syndrome.  As a result, Schoen notes that "over the past 30 years, the life expectancy of those with Down syndrome has more than doubled -- underscoring the importance of development of treatments that will assist this population to achieve and maintain independent living. Along with other organizations supporting Down syndrome cognitive research, such as Down Syndrome Research and Treatment Foundation (DSRTF), we believe that individuals with Down syndrome should have access to effective drug therapies in a manner consistent with many medical conditions."

The RDS outreach program goal is to broaden awareness of Down syndrome cognitive research on a larger scale beyond the Down syndrome community -- communicating new research and scientific breakthroughs, and encouraging people to spread the news and support this research. http://www.researchds.org;  http://www.youtube.com/ResearchDownSyndrome.

Down syndrome is the result of an extra copy of the genetic material present on chromosome 21. It is the most frequently occurring chromosomal abnormality, with an incidence of approximately 1 of every 700 live births. Currently there are an estimated three million persons with Down syndrome worldwide, including approximately 400,000 in the United States. The extra chromosomal material impacts the body's and brain's normal development and manifests differently in each individual, including physical traits such as short stature and low muscle tone, and health conditions such as congenital heard defects and hearing deficits.

In addition to Johns Hopkins University, RDS supports cognitive research at other leading research institutions that are studying the basis of the intellectual impairments associated with Down syndrome, including Stanford University, The University of Arizona, University of California, San Diego, and University of Colorado.

About Research Down Syndrome

Research Down Syndrome (RDS) is a non-profit foundation which funds research at leading institutions directed towards identifying safe and effective biomedical therapies to treat the intellectual difficulties associated with Down syndrome. RDS' mission is to educate and inspire society to fund and support Down syndrome cognitive research to enhance and expand life opportunities, helping people with Down syndrome lead more independent lives. Research Down Syndrome is a legal corporate entity, and is a 501(c) (3) nonprofit organization designated by the Internal Revenue Code.  For more information, go to www.researchds.org.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Robert Schoen, Ph.D.

http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=94121

SOURCE Research Down Syndrome

Back to top

RELATED LINKS
http://www.researchds.org

'/>"/>

SOURCE Research Down Syndrome
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sandia, SRC win LES award for NINE program outreach
2. Medication Adherence Technology Combines with Patient Outreach Program to Yield Healthier Populations and Reduce Healthcare Costs
3. Shire Initiates Two Adult ADHD Outreach Programs
4. New Source for Science Funding: BenchFly Pioneers Search for Research Program
5. UC San Diegos Biotech Demystified Program Offers Science Basics for Industry Leaders
6. Texas-Based Consortium Announces Project GreenVax: A Groundbreaking Vaccine Manufacturing Research Program
7. CJP Announces 5 Days Global Jatropha Hi-Tech Agricultural Training Programme in India from SEPTEMBER 20-24, 2010
8. Davis Phinney Foundation Launches Every Victory Counts Program to Inform and Empower People to Live Well With Parkinsons
9. Therapeutic Cells Derived From Reprogrammed (iPS) Stem Cells Display Early Aging
10. NVHR: Stop Liver Cancer Dead in Its Tracks By Closing Funding Gap for Viral Hepatitis Education, Screening Programs
11. Sudek of Tech Coast Angels Announces Networks Increased Commitment to Entrepreneurship and Innovation Through New Easy-Access Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Malden, MA (PRWEB) , ... February 24, 2017 ... ... disc replacement (TDR) procedures can be safely completed in an ambulatory surgery center ... and fusion (ACDF) procedures and previous two-year TDR studies. , Jake Lubinski, ...
(Date:2/24/2017)... 2017 Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, ... clinical-stage oncology and dermatology biopharmaceutical company, today is ... in its previously announced rights offering of up ... common stock and Series C Convertible Preferred Stock ... As previously announced, the rights ...
(Date:2/24/2017)...  Driven by consumers, preference towards more natural ... growing categories, finds the recently published U.S. volume ... Multi-regional Market Analysis and Opportunities study by ... "Biotechnology actives are derived from natural ... for skin and hair care applications," explains ...
(Date:2/24/2017)... Feb. 23, 2017 China Biologic Products, Inc. (NASDAQ: ... plasma-based biopharmaceutical company in China, today announced its financial results ... Fourth Quarter 2016 Financial Highlights ... by 21.7% in RMB terms, or increased by 13.6% in ... same quarter of 2015. Gross profit increased ...
Breaking Biology Technology:
(Date:2/16/2017)... Feb. 16, 2017  Genos, a community for ... it has received Laboratory Accreditation from the College ... presented to laboratories that meet stringent requirements around ... rigorous processes. "Genos is committed to ... practices. We,re honored to be receiving CAP accreditation," ...
(Date:2/10/2017)... 2017 Research and Markets has ... Medicine - Scientific and Commercial Aspects" to their offering. ... ... integrated with therapy for selection of treatment as well for ... prevention of disease in modern medicine. Biochip/microarray technologies and next ...
(Date:2/8/2017)... Report Highlights ... The global synthetic-biology market reached nearly $3.9 ... growing at a compound annual growth rate (CAGR) of 24.0% ... global markets for synthetic biology. - Analyses of global market ... of compound annual growth rates (CAGRs) through 2021. - Coverage ...
Breaking Biology News(10 mins):